{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T21:59:01Z","timestamp":1767650341208},"reference-count":5,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"18","content-domain":{"domain":["www.ahajournals.org"],"crossmark-restriction":true},"short-container-title":["Circulation"],"published-print":{"date-parts":[[2016,11]]},"DOI":"10.1161\/circulationaha.116.023264","type":"journal-article","created":{"date-parts":[[2016,9,13]],"date-time":"2016-09-13T02:19:05Z","timestamp":1473733145000},"page":"1311-1313","update-policy":"http:\/\/dx.doi.org\/10.1161\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":13,"title":["Should Patients With Cardiovascular Risk Factors Receive Intensive Treatment of Hypertension to <120\/80 mm\u2009Hg Target?"],"prefix":"10.1161","volume":"134","author":[{"given":"Eva M.","family":"Lonn","sequence":"first","affiliation":[{"name":"From the Department of Medicine and Population Health Research Institute, McMaster University and Hamilton Health Sciences, Ontario, Canada (E.M.L., S.Y.)."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Salim","family":"Yusuf","sequence":"additional","affiliation":[{"name":"From the Department of Medicine and Population Health Research Institute, McMaster University and Hamilton Health Sciences, Ontario, Canada (E.M.L., S.Y.)."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1001286"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)60852-1"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1511939"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(98)04311-6"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1600175"}],"container-title":["Circulation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ahajournals.org\/doi\/full\/10.1161\/CIRCULATIONAHA.116.023264","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,13]],"date-time":"2024-05-13T06:58:59Z","timestamp":1715583539000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ahajournals.org\/doi\/10.1161\/CIRCULATIONAHA.116.023264"}},"subtitle":["An Antagonist View From the HOPE-3 Trial (Heart Outcomes Evaluation-3)"],"short-title":[],"issued":{"date-parts":[[2016,11]]},"references-count":5,"journal-issue":{"issue":"18","published-print":{"date-parts":[[2016,11]]}},"alternative-id":["10.1161\/CIRCULATIONAHA.116.023264"],"URL":"https:\/\/doi.org\/10.1161\/circulationaha.116.023264","relation":{},"ISSN":["0009-7322","1524-4539"],"issn-type":[{"value":"0009-7322","type":"print"},{"value":"1524-4539","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,11]]},"assertion":[{"value":"2016-09-12","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}